benefits of glp 1 agonists EASD 2018: GIP/GLP-1 receptor co-agonists in T2D Therapeutic benefits of glucagon-like peptide-1
Description
International Journal of Obesity, 37(11), 14431451
Support og tilgngelighed spiller en lige s vigtig rolle som udvalget af spil
Note: The 0.6 mg Victoza dose is intended to reduce gastrointestinal symptoms and is not an effective dose for glycemic control
doi: 10.1038/s41569-021-00536-1, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 83
SGLT2i have consistently demonstrated cardiovascular benefits in meta-analyses and recent studies, confirming their robust efficacy regardless of ejection fraction or the presence of diabetes
Month 3 and beyond: Patients who respond tend to continue responding
